21 Apr NexPlasmaGen receives financial support from the Québec Ministry of Economy, Innovation and Energy, and the Québec Breast Cancer Foundation
Montreal / April 21, 2023 – NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l’économie, de l’innovation et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet medical device, for breast cancer patients.
This funding comes from the MEI PSO technology maturation program – component 2d managed by Axelys. The project consists of Phase 1 clinical trials for the treatment of a tumor bed with cold plasma after a breast lumpectomy.
“Receiving this funding from institutions such as the MEI and the QBCF is truly an honor. This support is crucial to validate the safety of our device in breast cancer patients for the very first time,” said Dr. Valérie Léveillé, CEO of NexPlasmaGen.
NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the potential to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.
Valérie Léveillé, CEO/Founder
1-514-229-9458, email@example.com, https://nexplasmagen.com/